Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6916 to 6930 of 8223 results

  1. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued Reference number: GID-TA11259

    Technology appraisal guidance
    Discontinued

  2. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued Reference number: GID-TA11260

    Technology appraisal guidance
    Discontinued

  3. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued Reference number: GID-TA11261

    Technology appraisal guidance
    Discontinued

  4. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued Reference number: GID-TA11262

    Technology appraisal guidance
    Discontinued

  5. Alzheimer's disease (early) - gantenerumab [ID6142]

    In development Reference number: GID-TA11269 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Depemokimab for treating chronic rhinosinusitis with nasal polyps [ID6449]

    In development Reference number: GID-TA11542 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Moxetumomab pasudotox for treating hairy-cell leukaemia [ID1142]

    Discontinued Reference number: GID-TA10923

    Technology appraisal guidance
    Discontinued

  8. Dostarlimab with docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6530]

    Discontinued Reference number: GID-TA11655

    Technology appraisal guidance
    Discontinued

  9. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    In development Reference number: GID-TA10895 Expected publication date:  29 October 2026

    Technology appraisal guidance
    In development

  11. Spesolimab for preventing generalised pustular psoriasis flares in people 12 years and over [TSID12086]

    In development Reference number: GID-TA11709 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  13. Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer [ID6316]

    In development Reference number: GID-TA11365 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    In development Reference number: GID-TA10779 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued